MSLN and ovarian carcinoma: The elevated expression of MSLN was correlated with poorer prognoses in patients with ovarian cancer [29], cholangiocarcinoma [30, 31], lung adenocarcinoma [29, 32], triple negative breast cancer [4, 33] and resectable pancreatic adenocarcinoma [34–36].